Difference between revisions of "Interferon alfa-2a (Roferon-A)"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.gene.com/gene/products/information/ | + | Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.<ref name="insert">[http://www.gene.com/gene/products/information/roferon-a/pdf/pi.pdf Interferon alfa-2a (Roferon-A) package insert]</ref><ref>[http://hemonc.org/docs/packageinsert/interferonalfa-2a.pdf Interferon alfa-2a (Roferon-A) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: SC |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
| Line 8: | Line 8: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]<ref>[http://chemocare.com/BIO/interferon_alfa.asp Interferon alfa-2a (Roferon-A) patient drug information (Chemocare)]</ref> | ||
| − | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 16:48, 22 February 2012
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].